

Euromedica - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

Lareb

*Nederlands Bijwerkingen Centrum
Netherlands Pharmacovigilance Centre*

The role and operation of consumer reporting in the Netherlands

Pharmacovigilance in 2015
Current perspectives and future challenges
December 2, 2014

Dr. Linda Härmak, PharmD

WHO Collaborating Centre for
Pharmacovigilance in Education and Patient
reporting

www.lareb.nl

Euromedica - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

Consumer reporting

Patient reporting

Reporting from the general public

Definition consumer reporting

A consumer report is a report of a suspected adverse reaction to a medicinal product as initiated by the consumer and without interpretation by a health-care professional.

Why consumer reporting?

CURRENT OPINION

Drug Safety 2003; 26 (4): 211-217
0114-5916/03/0004-0211/\$30.00/0

© Adis International Limited. All rights reserved.

Consumer Adverse Drug Reaction Reporting A New Step in Pharmacovigilance?

Kees van Grootheest,¹ Linda de Graaf¹ and Lolkje T.W. de Jong-van de

- 1 Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands
- 2 Department of Social Pharmacy and Pharmacoepidemiology, Groningen University for Drug Exploration, Groningen, The Netherlands

Abstract

The direct reporting of adverse drug reactions has become an increasingly important topic for discussion in the world.

Review

General

Patients' role in reporting adverse drug reactions

Kees van Grootheest[†] & Lolkje de Jong-van den Berg


[†]The Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands

Patient reporting of suspected adverse drug reactions:
a review of published literature and
international experience

Trial consumer reporting 2003

- In April 2003 trial with accepting consumer reports
- First year almost 300 consumer reports
- The reports from consumers contained enough medical information to be useful to pharmacovigilance

Number of reports 2000 -2013



WHAT IS THE CONTRIBUTION OF PATIENT REPORTS TO PHARMACOVIGILANCE?

Three years of experience with consumer reporting in the Netherlands

- Similarities found in age, sex, most frequently reported ADRs and most frequently reported drugs
- Differences between consumer- and healthcare professional reports in the categories of seriousness and outcome of the reported ADRs


Consumer's motivation for reporting ADRs

- Consumer characteristics of reporters
- *Altruism* is an important factor for reporting ADRs
- The *severity of ADR* and *need to share experiences* the main motives to report

Consumers's quotes about motives for reporting

...my motive is that this is information that has to be available to others and as Lareb collects this information I will report it to them. For me personally reporting doesn't make a difference, I want to recover, and I will arrange that with my general practitioner. But this reaction could also happen to someone else and that should be known. So again it's about making the adverse reaction known and taking care that the information is available...

Influence of media attention on consumer reporting



Comparison consumer and HP reports after media attention

- Media attention led to a peak in consumer reporting of ADRs but not in reporting by health professionals
- Qualitative analysis: **Impact on quality of life** through consumer reports!

Contribution of consumer reporting to signal detection

- Consumers contribute to disseminated signals about drug-ADR associations
- Consumers' reports of ADRs can provide a valuable contribution to the detection of signals
- This is ***additional*** to healthcare professionals' reports

Signal detection

- Duloxetine and electric shock sensation

Signal detection

- Duloxetine and electric shock sensation
- SSRIs and persistent sexual dysfunction

Signal detection

- Duloxetine and electric shock sensation
- SSRIs and persistent sexual dysfunction
- Cyproterone/ethinylestradiol and thromboembolic events

Signal detection

- Duloxetine and electric shock sensation
- SSRIs and persistent sexual dysfunction
- Cyproterone/ethinylestradiol and thromboembolic events
- Changes in packaging of levodopa and ADRs

Euromed - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”



EU legislation 2010

- Strengthen the European pharmacovigilance system
- Direct consumer reporting to national centers
- Implementation July 2012



Guideline

SAFETY MONITORING *of* **MEDICINAL PRODUCTS**

Reporting system for the general public



- 1. Why consumer reporting?
- 2. Definitions
- 3. How to start a consumer reporting system
- 4. Reporting of adverse reactions to medicines
- 5. Special issues in reporting
- 6. Practicalities in the organization of consumer reporting
- 7. Assessment of case reports
- 8. Use of the data
- 9. Relations with other parties

How to start a consumer reporting system

- A functional spontaneous reporting system for health-care professionals as a basis.
 - Staff with knowledge in handling spontaneous reports are already available
 - A reporting form has already been developed and can be adapted for consumer reporting
 - Procedures for assessing reports have already been established
 - A database for storing reports is probably available

How to start a consumer reporting system

- Get health authorities and consumer and patient organizations on board

Guideline

SAFETY MONITORING *of* **MEDICINAL PRODUCTS**

Reporting system for the general public



World Health
Organization

- 1. Why consumer reporting?
- 2. Definitions
- 3. How to start a consumer reporting system
- **4. Reporting of adverse reactions to medicines**
- 5. Special issues in reporting
- 6. Practicalities in the organization of consumer reporting
- 7. Assessment of case reports
- 8. Use of the data
- 9. Relations with other parties

Means of reporting

Table III. Method of adverse drug reaction report collection per country

Country	Telephone	Electronic forms	Paper forms
Australia	✓	✓	✓
Canada	✓	✓	✓
Denmark		✓	
Malaysia	✓		✓
Netherlands		✓	
New Zealand	✓	✓	✓
Norway		✓	
Philippines	✓		✓
Sweden		✓	✓
UK	✓	✓	✓
US	✓	✓	✓

✓ indicates method of reporting available.

Van Hunsel et al. Drug Safety 2012; 35 (1):45-60

Reporting form

- Accessibility
- Content

Europharma - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

Table IV. Specifications for electronic reporting forms^a

Country	Use of free-text in form	Mandatory fields in form	Forms automatically imported in database	Drop-down lists for selection of ADRs used in form	Drop-down list for selection of (co-) medication used
Australia (TGA)	Available	Available	Unknown	Not available	Not available
Australia (AME-Line)	Available	Not available	Not available	Not available	Not available
Canada	Available	Available	Not available	Not available	Not available
Denmark	Available	Available	Not available ^b	Not available	Available
Netherlands	Available	Available	Available	Not available	Available
New Zealand	Available	Not available	Not available	Not available	Not available
Norway	Available	Available	Available	Not available	Available
Sweden	Available	Available	Available	Not available	Not available
UK	Available	Available	Available	Available	Available
US	Available	Available	Unknown	Not available	Not available

a Electronic patient reporting forms were not available for Malaysia and the Philippines.

b At the time of the interview, the forms were not automatically imported in the database; in the new system that the Danish Medicines Agency uses, this will have changed.

ADRs = adverse drug reactions; **AME** = Adverse Medicines Events; **TGA** = Therapeutic Goods Administration.

Van Hunsel et al. Drug Safety 2012; 35 (1):45-60

Euopharma - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

Drug Saf (2014) 37:409–419
DOI 10.1007/s40264-014-0162-y

ORIGINAL RESEARCH ARTICLE

Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries

Florence Margraff · Delphine Bertram

Lareb

Lareb

- Different forms for HCPs and consumers
- Different forms for drugs and vaccines

Reporting of adverse drug reactions to medicines

- Means of reporting
- Reporting form
- What to report

What to report?

- ADRs of registered drugs
- Medications errors
- Counterfeit drugs
- Herbals and vitamins

Promotion

- Increase awareness
 - of the possibility: you can!
 - of the importance: you should!
- General
- Targeted

Euopharma - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

Magazine



Lareb

Promotion



Promotion

- General
- Targeted

Euopharma - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”



**bijwerkingen?
melden!**

daar wordt iedereen beter van
www.mijnbijwerking.nl

CBG Centraal Bureau Geneesmiddelen

Lareb

Lareb

Europharma - Konferencja „Pharmacovigilance w 2015 r. – nowa praktyka, szanse i zagrożenia”

geef uw mening

12-09-2014 **Mirena spiraal (levonorgestrel)**
Vrouw (43) - Anticonceptie...

Algehele tevredenheid: ★★★★★

In nov 2009 is bij mij het mirena spiraaltje geplaatst. Ik heb ong 2jaar last gehad van bloedingen, te pas en te onpas. Na Meerdere keren, vd huisarts medicatie gehad om het bloeden te laten stoppen was het na zon 2 jaar dan eindelijk over. Toen een jaar lang zo af en toe een bloeding en daarna ruim 1 1/2 jaar helemaal niets meer. Sinds een tijdje heb ik een rare gee [lees meer...]

	Tevredenheid over
Effectiviteit	★★★★★
Hoeveelheid bijwerkingen	★★★★★
Ernst bijwerkingen	★★★★★
Inname- / gebruiksgemak	★★★★★

Reageer op deze ervaring

12-09-2014 **Mirena spiraal (levonorgestrel)**
Vrouw (48) - Overgang

Algehele tevredenheid: ★★★★★

I.v.m. hevig vloeien met stolses met als gevolg een heel laag hb tijdens de overgang werd een Mirenaspiraal geplaatst door de gynaecoloog. Het inbrengen verliep snel en pijnloos (tot verbazing van de gynaecoloog). De menstruaties werden minder en bleven na een paar maanden weg. Na een half jaar begonnen bijwerkingen; ineens afvallen, extreem rusteloos gevoel, depressief, n [lees meer...]

	Tevredenheid over
Effectiviteit	★★★★★
Hoeveelheid bijwerkingen	★★★★★
Ernst bijwerkingen	★★★★★
Inname- / gebruiksgemak	★★★★★

1 Reactie



Kijk hier voor informatie over zwangerschap.

LET OP!

Ervaringen zijn persoonlijk en de werking van medicijnen verschilt per persoon. Raadpleeg altijd uw arts en/of apotheker voor passend advies. Zie ook bij « veelgestelde vragen » het doel van mijnmedicijn.nl.

+ DOKTER ONLINE

We bieden een ruim assortiment aan anticonceptie-methoden.

Meer informatie ▶

www.dokteronline.com

Lareo

Consumer and patient organisations

- Questionnaires
- Screening of reported ADRs
- Respondents asked to fill in the reporting form

Consumer and patient organisations

- Good respons (25%)
- Willingness to provide follow up information
- Reports contribute to signal detection

Guideline

SAFETY MONITORING *of* **MEDICINAL PRODUCTS**

Reporting system for the general public



- 1. Why consumer reporting?
- 2. Definitions
- 3. How to start a consumer reporting system
- 4. Reporting of adverse reactions to medicines
- 5. Special issues in reporting
- **6. Practicalities in the organization of consumer reporting**
- **7. Assessment of case reports**
- 8. Use of the data
- 9. Relations with other parties

Handling of consumer ADR reports

- Differences in route of handling
 - Coding
 - Assessment
 - Feedback
 - Follow-up

Example of Feedback from NL

**Dear (name reporter),
Thank you for reporting to the Netherlands
Pharmacovigilance Centre Lareb. Your report has been
registered under the number 12345.**

Lareb recently published about aggressive behavior during the use of antidepressant medication (SSRIs). Aggressive behavior is described in the official information leaflet of fluoxetine. This reaction is mainly seen in users under 18 years. The extent to which adverse drug reaction occur and which adverse drug reactions occurs varies per person. Unfortunately this cannot be predicted. Recovery of the aggressive behavior after withdrawal of fluoxetine is an indication for a causal relation.

**Your report will be included in the Lareb database. This is a database in which all adverse drug reactions of all drugs in the Netherlands are collected. In this way, Lareb gets a good overview of the safety of medicines and will take action if necessary.
Thank you again for reporting.
Best regards,**

Handling of consumer ADR reports

- Differences in route of handling
 - Coding
 - Assessment
 - Feedback
 - Follow-up
- Duplicate detection
- Sharing reports with international databases
- Signal detection

April 23-24, 2015
Leiden, The Netherlands

Lareb conference on patient reporting

Current perspectives and future possibilities

A possibility for participants to meet experts in the field of patient reporting and to discuss challenges and opportunities.

For more information, please visit
www.lareb.nl/whocc

Europharma - Konferencja „Pharmacovigilance w 2015 r.
– nowa praktyka, szanse i zagrożenia”

- The role of the patient in pharmacovigilance
- The added value of patient reports to pharmacovigilance
- Maintaining and developing patient reporting systems
- Promoting patient reporting systems

Lareb
Netherlands Pharmacovigilance Centre



WHO Collaborating Centre for
Pharmacovigilance in Education
and Patient Reporting

Lareb

Take home message

- Consumer reporting of ADRs helps to broaden our insights on the safety of drugs, which is ultimately the goal of all our pharmacovigilance activities

Patients want to share their experiences when they have suffered from unpleasant effects of medicines.

Society needs to listen to patients to learn, and to improve the safety and safe use of medicines.

